Clinical Trials for Esophageal Cancer

A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1311 in Subjects With Advanced/Metastatic Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated, unresectable advanced or metastatic solid tumors and ECOG performance status 0–1 receive intravenous DB-1311/BNT324 every 21 days in dose-escalation or tumor-specific expansion cohorts. DB-1311/BNT324 is an investigational B7-H3–targeted antibody–drug conjugate that delivers a topoisomerase I inhibitor payload; prior B7-H3–targeted therapy or a topoisomerase inhibitor–payload ADC is excluded.

ClinicalTrials.gov ID: NCT05914116

Safety and Efficacy of Brodalumab in the Treatment of Immune-Related Adverse Events: A Pilot Study

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: This trial enrolls adults with advanced or metastatic solid tumors who developed IL-17–mediated immune-related adverse events after immunotherapy and require systemic steroids, testing brodalumab (an IL-17 receptor A inhibitor) as a potential steroid-sparing treatment for irAEs. Patients receive subcutaneous brodalumab alongside a planned steroid taper.

ClinicalTrials.gov ID: NCT06673329

A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy and in Combination With Anticancer Therapies in Participants With Selected Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced or metastatic solid tumors that have progressed on standard therapy or cannot receive it are treated with the oral selective CDK2 inhibitor INCB123667, which targets cyclin E1–CDK2–mediated cell-cycle progression. It is given alone or with palbociclib, ribociclib, fulvestrant, bevacizumab, olaparib, or paclitaxel, with combination cohorts focused on HR-positive/HER2-negative breast and epithelial ovarian cancers.

ClinicalTrials.gov ID: NCT05238922

A First in Human Phase I Trial of Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR T Cells in Patients With Advanced HER2 Positive Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced, refractory solid tumors and an injectable lesion receive intratumoral CAdVEC alone or followed by autologous HER2-specific CAR T cells; HER2 positivity is required only for the combination cohorts. CAdVEC is an oncolytic adenovirus designed to destroy tumor cells and deliver IL-12, PD-L1 blockade, and a safety switch.

ClinicalTrials.gov ID: NCT03740256

A Phase 1a/1b Multicenter, Open-label Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of PLN-101095 as Monotherapy and in Combination With Pembrolizumab in Adult Participants With Advanced or Metastatic Solid Tumors Who Have Disease Progression While on Pembrolizumab

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable advanced or metastatic solid tumors that progressed after at least 3 months of pembrolizumab, and who have no effective treatment options, receive oral PLN-101095 alone or with continued pembrolizumab. PLN-101095 inhibits αvβ8 and αvβ1 integrins to reduce activation of immunosuppressive TGF-β in the tumor microenvironment.

ClinicalTrials.gov ID: NCT06270706

Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with metastatic GI cancers (esophagus/GEJ/gastric, small bowel, colorectal/appendiceal, biliary, HCC, pancreatic/ampullary) on a benefiting systemic regimen who develop up to 5 new/progressing lesions receive lesion-directed local ablation (SABR or IR ablation) while continuing the same systemic therapy. Aims to control oligoprogression and delay systemic therapy change; excludes contraindications to ablation or active brain progression.

ClinicalTrials.gov ID: NCT06101277

Phase 1/2 Dose Escalation and Cohort Expansion Study Evaluating MCLA-158 (Petosemtamab) as Single Agent or in Combination in Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Open cohorts enroll patients with unresectable or metastatic microsatellite-stable, RAS/RAF wild-type colorectal cancer and ECOG 0–1; combination cohorts require no prior anti-EGFR therapy. Patients receive petosemtamab, an investigational EGFR/LGR5-targeting bispecific antibody, alone or with pembrolizumab, FOLFIRI, or FOLFOX.

ClinicalTrials.gov ID: NCT03526835

Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with metastatic GI adenocarcinomas (colorectal, pancreaticobiliary, or upper GI) progressing after standard therapy receive sacituzumab govitecan (Trop-2–targeted ADC delivering SN-38/topoisomerase I inhibitor) plus capecitabine in 21-day cycles; prior topo I inhibitor exposure is excluded, treated/stable brain mets allowed. Dose-escalation assesses safety/tolerability and seeks an RP2D, with exploratory correlation to tumor Trop-2 expression.

ClinicalTrials.gov ID: NCT06065371

A Phase 1 Study of TJ033721 in Subjects with Advanced or Metastatic Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Patients with advanced or metastatic solid tumors after standard therapy, or without a suitable standard option, receive givastomig alone; dose-expansion patients must have CLDN18.2-positive tumors. A separate group of treatment-naïve patients with CLDN18.2-positive, unresectable or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma receives givastomig with nivolumab and chemotherapy; givastomig is a bispecific antibody that targets CLDN18.2 and provides 4-1BB–mediated T-cell costimulation.

ClinicalTrials.gov ID: NCT04900818

Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab Versus Paclitaxel + Ramucirumab in Patients With PD-L1 CPS >/= 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with unresectable/metastatic, HER2‑negative, microsatellite‑stable gastric/GEJ/esophageal adenocarcinoma with PD‑L1 CPS ≥1 after exactly one prior PD‑1/PD‑L1–chemotherapy regimen are randomized to paclitaxel plus ramucirumab with or without nivolumab. Nivolumab is a PD‑1–blocking antibody; ramucirumab is a VEGFR2 antagonist, and paclitaxel is a microtubule stabilizer.

ClinicalTrials.gov ID: NCT06203600